Drug Profile

Research programme: mitochondrial targeting peptide therapeutics - CAMP Therapeutics

Alternative Names: CMP-3013

Latest Information Update: 20 Jan 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Preclinical Acute kidney injury; Autistic disorder; Barth syndrome; Dry age-related macular degeneration; Leber's hereditary optic atrophy; Leigh disease; MELAS syndrome; Peripheral nervous system diseases; Renal failure

06 Dec 2022 Preclinical trials in Acute kidney injury in South Korea (unspecified route) (CAMP Therapeutics pipeline, December 2022)
06 Dec 2022 Preclinical trials in Autistic disorder in South Korea (unspecified route) (CAMP Therapeutics pipeline, December 2022)
06 Dec 2022 Preclinical trials in Barth syndrome in South Korea (unspecified route) (CAMP Therapeutics pipeline, December 2022)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com